RE:RE:RE:Paul I would not totally rule that option out but it seems unlikely to be the best way to maximize shareholder value given it would be a fire sale and not one based on strength. And exactly who is wanting to buy two small HIV drugs anyway. Probably only a financial buyer who wants to buy on the cheap and run the company for cash to get a return. So, this is likely not a great option other than for investors who just want to move on and will take a hit to do so.
Trogarzon wrote: How about putting a strategic review plan to sell the company to the highest bidder. How could that be done. Collectively decide that this might just be the best way forward for shareholder value.